Sign In
Buy OPY
$106.64
-4.06 (-3.67%)
At Close: Jul 31, 2026
Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference
08:00am, Monday, 03'rd Feb 2025
CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host vi
Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
07:30am, Monday, 03'rd Feb 2025
WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics f
Oppenheimer Holdings Inc. Reports Fourth Quarter and Full Year 2024 Earnings
08:00am, Friday, 31'st Jan 2025
NEW YORK , Jan. 31, 2025 /PRNewswire/ - Oppenheimer Holdings Inc. (NYSE: OPY) (the "Company" or "Firm") today reported net income of $10.7 million or $1.04 basic earnings per share for the fourth quar
NervGen Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
05:00pm, Wednesday, 29'th Jan 2025
Vancouver, Canada--(Newsfile Corp. - January 29, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today
INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
04:14pm, Wednesday, 29'th Jan 2025
PLYMOUTH MEETING, Pa. , Jan. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-ass
AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
04:00pm, Wednesday, 29'th Jan 2025
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron c
Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
08:00am, Monday, 27'th Jan 2025
JERUSALEM, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, anno
XTI Aerospace Adds David Oppenheimer to its Corporate Advisory Board
09:00am, Tuesday, 14'th Jan 2025
ENGLEWOOD, Colo. , Jan. 14, 2025 /PRNewswire/ -- XTI Aerospace, Inc. (Nasdaq: XTIA) ("XTI Aerospace" or the "Company"), a pioneer in VTOL and Powered-Lift aircraft solutions, today announced that Davi
Shake Shack, Darden, Yum! 'Top Picks' for 2025 Says Oppenheimer
03:15pm, Tuesday, 07'th Jan 2025
Olive Garden, KFC, and Shake Shack look like particularly appetizing investments in 2025, according to Oppenheimer analysts.
Oppenheimer Thinks the Stock Market Will Surge 20% in 2025. 1 Stock To Buy Before it Does
01:05pm, Monday, 06'th Jan 2025
It's a new year, and with that, the 2025 S&P 500 forecasts from the big names on Wall Street are in.
Roper Technologies assumed with an Outperform at Oppenheimer
04:49pm, Friday, 20'th Dec 2024
Oppenheimer analyst Ken Wong assumed coverage of Roper Technologies with an Outperform rating and $630 price target. The firm sees potential for revenue acceleration with management targeting companie
Oppenheimer's Brian Nagel on Nike: The brand is still in tact
05:15pm, Thursday, 19'th Dec 2024
Brian Nagel, Oppenheimer senior analyst, joins 'Closing Bell: Overtime' to discuss Nike earnings and his outlook for the stock.
Oppenheimer Announces Expansion of Emerging Markets Desk
06:00am, Tuesday, 17'th Dec 2024
Strategic Recruitments of Persio 'Tony' Perez, Michael Chatman and Bill Dolan as Managing Directors Builds on Growth Momentum of Fixed Income Team Senior-Level Hires Enhance Oppenheimer's Capabilities
McGrath to Participate in the Oppenheimer Midwest Virtual Summit
04:01pm, Monday, 09'th Dec 2024
LIVERMORE, Calif.--(BUSINESS WIRE)--McGrath RentCorp (“McGrath” or the “Company”) (Nasdaq: MGRC), a leading business-to-business rental company in North America, today announced that Joe Hanna
Positive from Lululemon earnings is 'things did not get worse', says Oppenheimer's Brian Nagel
05:24pm, Thursday, 05'th Dec 2024
Brian Nagel, Oppenheimer senior equity research analyst, joins 'Closing Bell Overtime' to talk Lululemon quarterly results.
